|
JP5969471B2
(ja)
|
2010-07-22 |
2016-08-17 |
ギリード・サイエンシズ・インコーポレーテッド |
パラミクソウイルス科ウイルス感染症を治療するための方法及び化合物
|
|
EP3143020B1
(en)
*
|
2014-05-13 |
2019-08-21 |
F. Hoffmann-La Roche AG |
Dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
|
|
TWI740546B
(zh)
|
2014-10-29 |
2021-09-21 |
美商基利科學股份有限公司 |
製備核糖苷的方法
|
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
|
JP6435054B2
(ja)
*
|
2015-02-11 |
2018-12-05 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染の治療及び予防のための新規２−オキソ−６，７−ジヒドロベンゾ［ａ］キノリジン−３−カルボン酸誘導体
|
|
JP6462155B2
(ja)
|
2015-05-04 |
2019-01-30 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染症の治療用のＨＢｓＡｇ（ＨＢＶ表面抗原）及びＨＢＶ ＤＮＡ産生の阻害剤としてのテトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
|
|
US10179131B2
(en)
|
2015-07-13 |
2019-01-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2017016921A1
(en)
*
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
EP3328855B1
(en)
|
2015-07-27 |
2019-05-15 |
H. Hoffnabb-La Roche Ag |
Novel tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
|
CN107835813B
(zh)
|
2015-07-28 |
2020-04-24 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的6,7-二氢吡啶并[2,1-a]酞嗪-2-酮类化合物
|
|
CN114366745A
(zh)
|
2015-09-16 |
2022-04-19 |
吉利德科学公司 |
治疗沙粒病毒科和冠状病毒科病毒感染的方法
|
|
JP7016809B2
(ja)
|
2016-02-19 |
2022-02-07 |
ノバルティス アーゲー |
抗ウイルス剤としての四環式ピリドン化合物
|
|
CN109069488B
(zh)
|
2016-03-07 |
2021-09-07 |
英安塔制药有限公司 |
乙型肝炎抗病毒剂
|
|
SG11201809893WA
(en)
|
2016-05-27 |
2018-12-28 |
Gilead Sciences Inc |
Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
|
|
BR102017010009A2
(pt)
*
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
KR20190027814A
(ko)
|
2016-06-10 |
2019-03-15 |
이난타 파마슈티칼스, 인코포레이티드 |
B형 간염 항바이러스제
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
MA45496A
(fr)
*
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
|
WO2018011162A1
(en)
*
|
2016-07-14 |
2018-01-18 |
F. Hoffmann-La Roche Ag |
Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
|
|
CA3031063A1
(en)
*
|
2016-07-29 |
2018-02-01 |
Newave Pharmaceutical Inc. |
Benzo-quinolizin-2oxo carboxylic acid derivatives for the treatment of hbv infection
|
|
CN107759585A
(zh)
*
|
2016-07-29 |
2018-03-06 |
银杏树药业(苏州)有限公司 |
一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
WO2018041873A1
(en)
*
|
2016-09-01 |
2018-03-08 |
F. Hoffmann-La Roche Ag |
Process for the preparation of (6s)-6-isopropyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
EP3507276B1
(en)
|
2016-09-02 |
2021-11-03 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
US10640499B2
(en)
|
2016-09-02 |
2020-05-05 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
TW201811788A
(zh)
|
2016-09-09 |
2018-04-01 |
瑞士商諾華公司 |
作為抗病毒劑之多環吡啶酮化合物
|
|
CN117402852A
(zh)
|
2016-10-14 |
2024-01-16 |
精密生物科学公司 |
对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶
|
|
TW201819380A
(zh)
|
2016-10-18 |
2018-06-01 |
瑞士商諾華公司 |
作為抗病毒劑之稠合四環吡啶酮化合物
|
|
US11124495B2
(en)
|
2016-11-03 |
2021-09-21 |
Hoffmann-La Roche, Inc. |
Tetrahydroisoquinolines and terahydronaphthyridines for the treatment of hepatitis B virus infection
|
|
US10968218B2
(en)
|
2016-11-03 |
2021-04-06 |
Hoffmann-La Roche Inc. |
Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infection
|
|
JP7068295B2
(ja)
|
2016-11-03 |
2022-05-16 |
エフ．ホフマン－ラ ロシュ アーゲー |
Ｂ型肝炎ウイルス感染症の処置及び予防のための新規なテトラヒドロピリドピリミジン
|
|
US10821103B2
(en)
|
2016-11-07 |
2020-11-03 |
Arbutus Biopharma Corporation |
Substituted pyridinone-containing trycyclic compounds, and methods using same
|
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
|
CN106810548B
(zh)
|
2017-01-13 |
2019-02-15 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物
|
|
TWI820984B
(zh)
|
2017-01-31 |
2023-11-01 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
|
LT3587420T
(lt)
|
2017-02-23 |
2021-07-12 |
Fujian Cosunter Pharmaceutical Co., Ltd. |
Triciklis junginys ir jo naudojimas
|
|
KR102460968B1
(ko)
|
2017-03-14 |
2022-11-01 |
길리애드 사이언시즈, 인코포레이티드 |
고양이 코로나바이러스 감염의 치료 방법
|
|
CA3056886A1
(en)
|
2017-03-21 |
2018-09-27 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
AR111419A1
(es)
*
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
|
CN110636884B
(zh)
|
2017-05-01 |
2022-10-04 |
吉利德科学公司 |
新结晶形式
|
|
CN108530449B
(zh)
*
|
2017-05-22 |
2021-05-07 |
河南春风医药科技有限公司 |
用于治疗或预防乙型肝炎病毒感染的化合物及其制备方法与应用
|
|
CN110066278B
(zh)
*
|
2017-06-01 |
2021-06-08 |
广东东阳光药业有限公司 |
稠合三环类化合物及其在药物中的应用
|
|
TW201919648A
(zh)
|
2017-07-11 |
2019-06-01 |
美商基利科學股份有限公司 |
用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物
|
|
SG11202001685TA
(en)
|
2017-08-28 |
2020-03-30 |
Enanta Pharm Inc |
Hepatitis b antiviral agents
|
|
PL3692040T3
(pl)
*
|
2017-10-05 |
2023-04-17 |
Glaxosmithkline Intellectual Property Development Limited |
Związki chemiczne
|
|
IL310631A
(en)
|
2017-10-16 |
2024-04-01 |
Hoffmann La Roche |
Nucleic acid molecule to reduce papd5 and papd7 mRNA to treat hepatitis b infection
|
|
WO2019084271A1
(en)
|
2017-10-25 |
2019-05-02 |
Children's Medical Center Corporation |
PAPD5 INHIBITORS AND METHODS OF USE
|
|
EP3710455A1
(en)
|
2017-11-17 |
2020-09-23 |
Novartis AG |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
|
US10428070B2
(en)
|
2017-12-06 |
2019-10-01 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2019113175A1
(en)
|
2017-12-06 |
2019-06-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
AU2018392213B2
(en)
|
2017-12-20 |
2021-03-04 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
|
JP2021507906A
(ja)
*
|
2017-12-20 |
2021-02-25 |
ノバルティス アーゲー |
抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
|
|
AU2018392212B9
(en)
|
2017-12-20 |
2021-03-18 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
|
WO2019122393A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Bayer Aktiengesellschaft |
Hydroxyisoxazolines and derivatives thereof
|
|
EA038176B9
(ru)
*
|
2018-01-04 |
2021-09-07 |
Фуцзянь Косантер Фармасьютикал Ко., Лтд. |
Производные пирроло-[1,2,5]бензотиадиазепина и их применение для лечения заболевания, вызванного вирусом гепатита в
|
|
WO2019143902A2
(en)
|
2018-01-22 |
2019-07-25 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
KR102586510B1
(ko)
|
2018-02-13 |
2023-10-12 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
JP7050165B2
(ja)
|
2018-02-26 |
2022-04-07 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
|
|
US20200407365A1
(en)
|
2018-02-28 |
2020-12-31 |
Novartis Ag |
Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
|
|
WO2019177937A1
(en)
|
2018-03-12 |
2019-09-19 |
Arbutus Biopharma, Inc. |
Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
|
|
US10729688B2
(en)
|
2018-03-29 |
2020-08-04 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
KR20200142529A
(ko)
|
2018-04-12 |
2020-12-22 |
아뷰터스 바이오파마 코포레이션 |
치환된 피리디논-함유 트리사이클릭 화합물의 제조 방법
|
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
|
AU2019255750B2
(en)
|
2018-04-19 |
2021-10-21 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’－環二核苷酸
|
|
TWI862501B
(zh)
|
2018-07-03 |
2024-11-21 |
瑞士商赫孚孟拉羅股份公司 |
用於調制 Tau 表現之寡核苷酸
|
|
AU2019301811B2
(en)
|
2018-07-13 |
2022-05-26 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
TWI826492B
(zh)
|
2018-07-27 |
2023-12-21 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
US12128044B2
(en)
|
2018-08-28 |
2024-10-29 |
Sunshine Lake Pharma Co., Ltd. |
Fused tricyclic compounds and uses thereof in medicine
|
|
US10865211B2
(en)
|
2018-09-21 |
2020-12-15 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
EP3856740A4
(en)
|
2018-09-30 |
2021-12-15 |
Sunshine Lake Pharma Co., Ltd. |
CONDENSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
|
|
JP7158577B2
(ja)
|
2018-10-24 |
2022-10-21 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｐｄ－１／ｐｄ－ｌ１阻害剤
|
|
SG11202103839UA
(en)
|
2018-10-31 |
2021-05-28 |
Gilead Sciences Inc |
Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
|
|
KR102658602B1
(ko)
|
2018-10-31 |
2024-04-19 |
길리애드 사이언시즈, 인코포레이티드 |
Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
|
|
IL283190B2
(en)
|
2018-11-21 |
2025-08-01 |
Enanta Pharm Inc |
Functionalized heterocycles as antiviral agents
|
|
TW202415643A
(zh)
|
2018-12-12 |
2024-04-16 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
CN114014854B
(zh)
*
|
2019-01-08 |
2023-04-07 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物
|
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
CA3129011C
(en)
|
2019-03-07 |
2023-12-19 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
CA3129022C
(en)
|
2019-03-07 |
2023-08-01 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
CA3137768A1
(en)
|
2019-04-24 |
2020-10-29 |
Children's Medical Center Corporation |
Papd5 inhibitors and methods of use thereof
|
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
|
WO2020247444A1
(en)
|
2019-06-03 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
|
US11472808B2
(en)
|
2019-06-04 |
2022-10-18 |
Enanta Pharmaceuticals, Inc. |
Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
|
|
US11760755B2
(en)
|
2019-06-04 |
2023-09-19 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
CN114245807B
(zh)
|
2019-06-25 |
2025-05-02 |
吉利德科学公司 |
Flt3l-fc融合蛋白和使用方法
|
|
US11738019B2
(en)
|
2019-07-11 |
2023-08-29 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
US20220296619A1
(en)
|
2019-08-19 |
2022-09-22 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
WO2021055425A2
(en)
|
2019-09-17 |
2021-03-25 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
KR20220074917A
(ko)
|
2019-09-30 |
2022-06-03 |
길리애드 사이언시즈, 인코포레이티드 |
Hbv 백신 및 hbv를 치료하는 방법
|
|
WO2021113765A1
(en)
|
2019-12-06 |
2021-06-10 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
|
CN117736207A
(zh)
|
2019-12-24 |
2024-03-22 |
卡尔那生物科学株式会社 |
二酰基甘油激酶调节化合物
|
|
TWI789695B
(zh)
|
2020-01-27 |
2023-01-11 |
美商基利科學股份有限公司 |
治療sars cov-2感染之方法
|
|
JP7554841B2
(ja)
|
2020-03-12 |
2024-09-20 |
ギリアード サイエンシーズ， インコーポレイテッド |
１’－シアノヌクレオシドを調製する方法
|
|
WO2021188414A1
(en)
|
2020-03-16 |
2021-09-23 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocyclic compounds as antiviral agents
|
|
KR20220156884A
(ko)
|
2020-03-20 |
2022-11-28 |
길리애드 사이언시즈, 인코포레이티드 |
4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
|
|
KR102906891B1
(ko)
|
2020-04-06 |
2026-01-05 |
길리애드 사이언시즈, 인코포레이티드 |
1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형
|
|
WO2021228213A1
(zh)
*
|
2020-05-15 |
2021-11-18 |
福建广生堂药业股份有限公司 |
包含三并环类化合物的组合及其在制备治疗hbv药物中的应用
|
|
KR20230018473A
(ko)
|
2020-05-29 |
2023-02-07 |
길리애드 사이언시즈, 인코포레이티드 |
렘데시비르 치료 방법
|
|
JP2023531524A
(ja)
|
2020-06-24 |
2023-07-24 |
ギリアード サイエンシーズ， インコーポレイテッド |
１’－シアノヌクレオシド類似体及びその使用
|
|
WO2022031894A1
(en)
|
2020-08-07 |
2022-02-10 |
Gilead Sciences, Inc. |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
|
CN111943946B
(zh)
*
|
2020-08-19 |
2022-07-01 |
中国医学科学院医药生物技术研究所 |
含有氮杂环片段的二氢喹嗪酮羧酸类化合物及其应用
|
|
ES3015457T3
(en)
|
2020-08-24 |
2025-05-05 |
Gilead Sciences Inc |
Phospholipid compounds and uses thereof
|
|
AU2021331214B2
(en)
|
2020-08-27 |
2024-01-04 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
TW202344257A
(zh)
|
2020-10-16 |
2023-11-16 |
美商基利科學股份有限公司 |
磷脂化合物及其用途
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
WO2022241134A1
(en)
|
2021-05-13 |
2022-11-17 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
EP4346772A1
(en)
|
2021-05-26 |
2024-04-10 |
Gilead Sciences, Inc. |
Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
|
|
AU2022298639C1
(en)
|
2021-06-23 |
2025-07-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
JP7654118B2
(ja)
|
2021-06-23 |
2025-03-31 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
KR20240025616A
(ko)
|
2021-06-23 |
2024-02-27 |
길리애드 사이언시즈, 인코포레이티드 |
다이아실글리세롤 키나제 조절 화합물
|
|
CA3228162A1
(en)
|
2021-08-18 |
2023-02-23 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
KR20240154647A
(ko)
|
2022-03-02 |
2024-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
바이러스성 감염 치료를 위한 화합물 및 방법
|
|
JP2025508943A
(ja)
|
2022-03-02 |
2025-04-10 |
ギリアード サイエンシーズ， インコーポレイテッド |
ウイルス感染症の治療のための化合物及び方法
|
|
JP2025508941A
(ja)
|
2022-03-03 |
2025-04-10 |
ギリアード サイエンシーズ， インコーポレイテッド |
抗ウイルス化合物並びにその作製及び使用方法
|
|
CA3252494A1
(en)
|
2022-03-03 |
2023-09-07 |
Gilead Sciences, Inc. |
ANTIVIRAL COMPOUNDS AND THEIR MANUFACTURING AND USAGE PROCESSES
|
|
CA3257287A1
(en)
|
2022-06-06 |
2023-12-14 |
Gilead Sciences, Inc. |
METHODS OF TREATMENT OF VIRAL INFECTIONS INCLUDING SARS-CoV-2
|
|
EP4547334A1
(en)
|
2022-06-29 |
2025-05-07 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
EP4547665A1
(en)
|
2022-06-30 |
2025-05-07 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|
|
EP4665737A1
(en)
|
2023-02-16 |
2025-12-24 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
WO2025049699A1
(en)
|
2023-08-31 |
2025-03-06 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
US20250084088A1
(en)
|
2023-08-31 |
2025-03-13 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
US20250099476A1
(en)
|
2023-09-06 |
2025-03-27 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
US20250109157A1
(en)
|
2023-09-28 |
2025-04-03 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
US20250345389A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
US20250345390A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|